Hypera S.A. HYPE3
BMFBOVESPA · Brazil · Health Technology
BRL 24.61+0.13 (+0.53%)
Market open· · BRL · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · BRL · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Hypera SA (HYPMY) reports robust Q2 2026 results with 8.5% revenue growth, margin expansion, and strategic moves into high-growth GLP-1 and menopause treatment markets.
Hypera SA (HYPMY) reports a historic operating cash flow and outlines plans for growth in new markets, despite challenges in revenue and net income.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.